Estimates of AFib prevalence in the United States ranged from 2.7 million to 6.1 million individuals in 2010 and are predicted to double by 2050.2 Improved screening methods and increasing use of therapy methods have contributed to lower AFib mortality rates, which contributes to the increased number of patients living with the condition.3

Most adults develop AF later in life with the average age for men being 67 while the average age for women is 75.2 In general, the risk for developing AFib doubles every 10 years starting at age 60.3

The number of patients affected by AFib and the growth rate have made it a significant area of interest for healthcare providers and treatment options and methods continue to evolve. A long-term study over a 50-year period from 1958 to 2007 showed improved survival rates (25.4% decline in mortality) and a 73.5% decline in the risk of AFib-related stroke.3

Patient & Caregiver Resources

Some newly diagnosed patients find that connecting with others who have been diagnosed or care for those affected by AFib is a great way to cope with the feelings you may be experiencing and to ask questions and find answers. Connect with other on social networks like Facebook, post your questions on patient and caregiver community forums and contribute your own experiences to help others and become a more informed patient so you can make more information decisions about your treatment options, lifestyles choices and other factors that affect your quality of life living with AFib.

Below are a list of curated resources and communities to consider:

If you’ve recently been diagnosed with AFib, connect with others to share your experience or learn from theirs and become an informed patient so you can make educated decisions about your treatment options. Our frequently asked questions page for recently diagnosed patients may have some of the answers you’re looking for.

1 Bajpai A. Epidemiology and Ecomonic Burden of Atrial Fibrillation; 2007 US Cardiovascular Disease p14-17.
2 Davis- Leslie L. Contemporary management of atrial fibrillation. The Journal for Nurse Practitioners, 9(10): 643-52. 2013. https://www.sciencedirect.com/science/article/pii/S1555415513005254?via%3Dihub
3 Schnabel, R, Yin, X, Gona, P et al. Fifty-Year Trends in AFib Prevalence, Incidence, Risk Factors, NIHMSID, 2015

Caution: US law restricts this device to sale by or on the order of a physician. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions.

The NAVISTAR® THERMOCOOL®, EZ STEER® THERMOCOOL® NAV, THERMOCOOL® SF NAV, and THERMOCOOL SMARTTOUCH® Catheters are FDA approved for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible three-dimensional electroanatomic mapping systems. Catheter ablation for AF may not be an option for you if you have any of the following conditions: certain recent heart surgery; prosthetic valves; active systemic infection; certain cancers; intracardiac thrombus, or an interatrial baffle or patch. Consult your physician to find out if catheter ablation is right for you.

As with any medical treatment, individual results may vary. Only a cardiologist or electrophysiologist can determine whether ablation is an appropriate course of treatment. There are potential risks including bleeding, swelling or bruising at the catheter insertion site, and infection. More serious complications are rare, which can include damage to the heart or blood vessels; blood clots (which may lead to stroke); heart attack, or death. These risks need to be discussed with your doctor and recovery takes time.

THERMOCOOL® Navigation Catheters are indicated for the treatment of recurrent drug/device refractory sustained monomorphic ventricular tachycardia (VT) due to prior myocardial infarction (MI) in adults.